Elan and Transition enter Alzheimer’s agreement

AZD-103 is a small molecule compound in phase I clinical development that has the potential to both reduce disease progression and improve symptoms such as cognitive function in Alzheimer’s.

Under the terms of the agreement, Transition will receive upfront payments of $15 million and another two other payments totaling $15 million. In addition, dependant upon the successful development of AZD-103, Transition will be eligible to receive milestone payments of up to $185 million. Elan and Transition will share the costs and operating profits of AZD-103.

Elan commented that the agreement would increase their chances of making the drug successful.

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Elan is a company focused on developing treatments for neurological diseases.